fashion -WSS

fashion

author：focus 2025-09-03 03:37:19 - browse：3

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Hospital chaplains balance Covid safety with patients’ spiritual needs

WSS

Physician assistants need a new name. Here's what it should be

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Stories you might have missed in 2023: health, science, medicine

Study suggests new cause of Down syndrome: cells linked to aging

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

The cancer drug shortage isn’t new — and neither are the solutions

leisure time

fashion

entertainment

Medicare details structure of new drug price negotiation program

Stories you might have missed in 2023: health, science, medicine

Walensky prepares to leave CDC — and Congress — behind

Fauci's latest grilling in Congress: 9 hours, behind closed doors

How to save PrEP access — and even expand it

Hepatitis C has a cure — but many Americans still lack access to it

Alkermes shareholders re

Cancer drug shortages should be causing more outrage

Apple is now the first public company to be valued at $3 trillion

Drug repurposing or repositioning? The language matters

explore

Affirmative action in medical school literally saved lives

Activists slam private health insurers over coverage restrictions

Peter Hotez and the public health issue of online harassment

Medicare proposal to cover medical devices draws a mixed reaction

Profiling embryos to choose those with higher IQs is almost a reality

Wildfire smoke exposes gaps in outdoor worker protections

focus

hotspot

entertainment

explore